



# Sprint Bioscience

**Økonomisk Ugebrev Investor Conference**

Johan Emilsson, Chief Executive Officer

March 26, 2025

# Agenda

- Sprint Bioscience in brief
- Business & Development
- Programs & License deals
- Market insights
- Sprint Bioscience as an investment
- The team
- Summary

# Sprint Bioscience in brief

An innovative pharmaceutical company developing drug programs in preclinical phase for the treatment of cancer

## ● Purpose

*The majority of value in biotech deals is found at the pre-clinical stage, where Big Pharma consistently shows a preference for early partnerships. This approach gives them greater control over project development. They seek collaborations with experienced external developers—a role that Sprint Bioscience is perfectly positioned to fulfill*

# What we do – core competences

Comprehensive inhouse development capabilities



## Protein Science

Sprint Bioscience leverages expertise in protein interactions to develop targeted drugs, advancing molecular biology and disease understanding.



## Structural Biology

Sprint Bioscience utilizes 3D macromolecule structures to design targeted therapeutics and decode complex biological processes.



## Computational Chemistry

Sprint Bioscience employs advanced simulations to predict molecular interactions, streamlining drug design and reducing costs.



## Medicinal Chemistry

Sprint Bioscience integrates chemistry and pharmacology to design, synthesize, and optimize pharmaceutical agents, driving drug discovery and development.




## Cell Biology


Sprint Bioscience focuses on cellular mechanisms to identify biomarkers, validate drug targets, and advance targeted therapy development.

# Fragment-based drug discovery (FBDD)

## TAILOR-MADE FIT INTO THE PROTEIN POCKET



Biological molecule



Sprint Bioscience's molecule


- FBDD is a well-established approach **reducing attrition** (increasing probability of success) and providing leads for previously intractable targets
- **FBDD approach provides attractive advantages such as:**
  - Less R&D spending
  - Faster R&D time to lead compound
  - Offering diverse hits
  - Exhibiting multiple ways to develop novel compounds

## FBDD IS A PROVEN APPROACH

Drug	Mechanism	Indication	Approval	Company
Capivasertib	AKT	Breast cancer	2023	AstraZeneca
Asciminib	Allosteric BCR-ABL	CML	2021	Novartis
Sotorasib	Kras	NSCLC	2021	Amgen
Pexidartinib	CSF1R	Tenosynovial giant cell tumor	2019	Daiichi Sankyo
Erdafitinib	Tyrosine kinase inhibitor	Bladder cancer	2019	J&J
Venetoclax	BCL-2 inhibitor	Leukemia	2016	AbbVie
Vemurafenib	BRAF kinase inhibitor	Advanced melanoma	2011	Roche

**FBDD has played a central role in discovering seven FDA approved drugs, and another 50 fragment-derived compounds are currently in clinical development**


# Sprint Bioscience's business and revenue model




# Biotech financing

Sprint Bioscience vs. Traditional models

## Sprint Bioscience



## Traditional financing



# Reference case

Founded: 1993

HQ: Hamburg

Mkt Cap: 1,370 MUSD

Cash position: 419 MUSD

Other: Evotec has an extensive portfolio with over 200 research and development projects, spanning from early discovery to clinical development



Sprint Bioscience has the potential to follow Evotec's path by focusing on oncology and metabolic diseases, areas with high growth potential. Like Evotec in its early years, Sprint uses a lean model to quickly advance drug candidates to proof-of-concept, attracting pharma partnerships for further development. By continuing to build its pipeline and secure collaborations, Sprint can scale its portfolio and expertise. As it grows, Sprint could position itself as a trusted R&D partner, transforming into a key player in drug discovery, just as Evotec has done.

# Programs and partners

Programs	Indication	Target	FBDD Discovery	Preclinical	Clinical Development
VRK1	Solid tumors	→			LICENSED TO <b>Day One</b> Biopharmaceuticals
VPS34	Melanoma	→			
PETRA01	Leukemia	→			
TREX1	Solid tumors	→			
NNMT	Solid tumors	→			
STK25	MASH	→			
DCPS	Leukemia	→			
Undisclosed programs		→			

**Total potential deal value**

316 MUSD +  
Royalties

## Patents

Sprint Bioscience strategically positions its IP to optimize patent timing. This approach extends market exclusivity and maintains flexibility. With expertise in patent strategy and data readiness, drug candidates remain attractive to partners that may want to take part in forming an optimized IP positioning.

# Overview of Day One Biopharmaceuticals

Founded: 2018

HQ: San Francisco

Mkt Cap: +1,500 MUSD (Nov. 2024)

Cash position: 558 MUSD (nine months ended 9/30/24)


VRK1 program in-licensed from Sprint Bioscience in August 2023



Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Sprint  
Bioscience

# Business model – potential new ways to generate shareholder value



# Market insights – executed pharma deals 2023

~50%



Of total deal values  
are made in  
pre-clinical stage

~280

Approximate number of  
licensing deals in discovery-  
**and** preclinical stage

Sources: 1) National cancer institute, 2) Cortellis; Global data; Locust Walk Analysis, 3) IQVIA Pharma Deals

# Market insights – Discovery stage deals




Modality: Small molecules approx. 58 out of 180 deals in discovery stage

Source: Pullan's Pieces #198 November 2023

# THE TEAM



Johan Emilsson  
Chief Executive Officer



Martin Andersson  
Chief Scientific Officer



Anne-Marie Wentzel  
Chief Business Officer



Niklas Axelsson  
Chief Financial Officer



Björn Sjöstrand  
Chairman of the Board of  
Directors



Svein Mathisen  
Member of the Board of  
Directors



Rune Nordlander  
Member of the Board of  
Directors



Fredrik Lehmann  
Member of the Board of  
Directors



Karen From  
Member of the Board of  
Directors

# Sprint Bioscience as an investment



Proven Business model with unique platform



Attractive and diversified portfolio with scalability



Strong pipeline of programs



Active in a multibillion-dollar market



Existing and new potential partnerships



# Sprint Bioscience



Contact: Johan Emilsson, CEO  
[johan.emilsson@sprintbioscience.com](mailto:johan.emilsson@sprintbioscience.com)

[www.sprintbioscience.com](http://www.sprintbioscience.com)